Displaying publications 1 - 20 of 48 in total

Abstract:
Sort:
  1. Khandelwal A, Gupta A, Virmani V, Khandelwal K
    Med J Malaysia, 2012 Oct;67(5):534-5.
    PMID: 23770877
    Bacillus Calmette-Guérin (BCG) is a live attenuated strain of Mycobacterium bovis that has been used as effective treatment for early-stage transitional carcinoma of the urinary bladder. We present a case of a 68 year old man who had an abdominal aortic aneurysm following BCG therapy for bladder cancer. Contrast enhanced computerized tomogram (CECT) of abdomen and pelvis revealed bilateral hypodense lesions suggestive of psoas abscesses. In addition, a saccular abdominal aortic aneurysm measuring 4x3.6 cm involving infrarenal aorta with surrounding hematoma was seen. At surgery, he was found to have a psoas abscess and hemorrhage. He underwent ligation of the aorta and an axillary-bifemoral bypass. He was given one year of anti-tubercular therapy to which he responded clinically.
    Matched MeSH terms: BCG Vaccine
  2. Roy RN
    Bull Int Union Tuberc, 1972 Aug;47 Suppl 2:162-4.
    PMID: 4145661
    Matched MeSH terms: BCG Vaccine*
  3. Sinniah D, Nagalingam I, Chua CP, Khoo KP, Dugdale AE
    Clin Pediatr (Phila), 1974 Sep;13(9):765-6.
    PMID: 4429633 DOI: 10.1177/000992287401300913
    Matched MeSH terms: BCG Vaccine*
  4. Muthuvelu S, Lim KS, Huang LY, Chin ST, Mohan A
    BMC Pediatr, 2019 07 24;19(1):251.
    PMID: 31340782 DOI: 10.1186/s12887-019-1635-z
    BACKGROUND: Reactivation of the Bacillus Calmette-Guérin (BCG), manifesting as erythema, induration, ulceration or crust formation at a previous BCG inoculation site, is a common and highly specific feature of Kawasaki disease (KD). We report the unusual finding of BCG reactivation in an infant with laboratory-confirmed measles.

    CASE PRESENTATION: A previously healthy 7-month old infant presented initially with fever, cough and coryza, and subsequently developed Koplik's spots followed by a typical morbilliform skin rash. There was significant contact history with a household relative who had recently been diagnosed with measles. On examination, a 2.5 cm area of erythema and induration was seen at the previous BCG inoculation site, in addition to the widespread maculopapular rash. No other clinical features of KD were present. Measles virus was isolated from the throat swab and measles antibodies (IgM) were present in the serum. The patient recovered completely with oral vitamin A and supportive therapy, and had normal echocardiography examination on follow up.

    CONCLUSIONS: This case report highlights the rare finding of BCG reactivation in a child with confirmed measles infection, and suggests that this clinical manifestation may occasionally occur in children with infections or conditions other than KD.

    Matched MeSH terms: BCG Vaccine/immunology*
  5. SODHY JS
    Med J Malaysia, 1964 Jun;18:239-50.
    PMID: 14199442
    Matched MeSH terms: BCG Vaccine*
  6. Achdiat PA, Suwarsa O, Hidayat YM, Shafiee MN, Dwiyana RF, Gunawan H, et al.
    Hum Vaccin Immunother, 2023 Dec 31;19(1):2187591.
    PMID: 36942667 DOI: 10.1080/21645515.2023.2187591
    Anogenital Warts (AGWs) are benign proliferations caused by Human Papillomavirus (HPV) infection on the genital or anal areas. Various therapeutic options are available for the treatment of AGWs but there is no best or ideal therapy, and the recurrence of AGWs is significantly high. A promising new therapy that is currently being evaluated is immunotherapy with the intralesional Bacillus Calmette-Guérin (BCG) vaccine. Two cases of a 23-year-old woman and a 41-year-old man were presented with manifestations of condyloma acuminata type AGWs. The patients were immunocompetent and received single dose intralesional BCG vaccine on the largest lesion. Clinical improvements of AGWs lesions were noted starting on the 14th day after receiving therapy by the disappearance of some lesions with no recurrence and side effects. Intralesional BCG vaccine activates the immune system, treats other AGWs lesions that do not receive an intralesional injection, and also prevents recurrence. Although the intralesional BCG vaccine is effective for treating AGWs, further evaluation is still needed for its recurrence.
    Matched MeSH terms: BCG Vaccine/therapeutic use
  7. Rahman ZA, Hidayatullah F, Lim J, Hakim L
    Arch Ital Urol Androl, 2024 Feb 16;96(1):12154.
    PMID: 38363237 DOI: 10.4081/aiua.2024.12154
    INTRODUCTION: Local therapies for high risk non-muscle-invasive bladder cancer (NMIBC) such as intravesical chemotherapy (IVC) have shown a high rate of progression and recurrence. Intravesical Bacillus Calmette-Guérin (BCG) for local therapies has been shown to reduce progression and recurrence in patient with NMIBC. However, its potential role is limited in high burden countries for tuberculosis (TB) due to its low specificity that can cause wrong diagnosis or false positive in patients with clinically diagnosed tuberculosis. BCG vaccine that has to be given for most people in tuberculosis endemic countries will induce trained immunity that could reduce the effectivity of intravesical BCG for NMIBC. Moreover, intravesical BCG is contraindicated in patient with or previous tuberculosis. The potential clinical benefit of intraarterial chemotherapy (IAC) in delaying the recurrence and progression of high-risk NMIBC have been investigated with promising results. We aimed to conduct a meta-analysis to evaluate the potential anti-tumor effect of IAC in NMIBC.

    METHODS: We conducted a comprehensive search of published articles in Cochrane Library, Pubmed, and Science-Direct to identify relevant randomized controlled trials (RCTs) and observational studies comparing IAC alone or combined with IVC versus IVC/BCG alone in NMIBC. The protocol of preferred reporting items for systematic review and meta-analysis (PRISMA) was applied to this study.

    RESULTS: Four RCTs and 4 cohort observational studies were eligible in this study and 5 studies were included in meta-analysis. The risk ratio of tumor recurrence was reduced by 35% (RR = 0.65; 95% CI 0.49-0.87; p = 0.004) in IAC plus IVC, while recurrence-free survival (RFS) was prolonged by 45% (HR: 0.55; 95% CI, 0.44-0.69; p < 0.001). The risk of tumor progression was reduced by 45% (RR = 0.55; 95% CI 0.41-0.75; p = 0.002) and tumor progression-free survival (PFS) was also prolonged by 53% (HR: 0.47; 95% CI, 0.34-0.65; p<0.001). Some RCT's had high or unclear risk of bias, meanwhile 4 included cohort studies had overall low risk of bias, therefore the pooled results need to be interpreted cautiously. Subgroup analysis revealed that the heterogeneity outcome of tumour recurrence might be attributed to the difference in NMIBC stages and grades.

    CONCLUSIONS: The IAC alone or combined with IVC following bladder tumor resection may lower the risk of tumor recurrence and progression. These findings highlight the importance of further multi institutional randomized controlled trials with bigger sample size using a standardized IAC protocol to validate the current results.

    Matched MeSH terms: BCG Vaccine/therapeutic use
  8. Razack AH
    Asian J Surg, 2007 Oct;30(4):302-9.
    PMID: 17962138 DOI: 10.1016/S1015-9584(08)60045-7
    Bladder cancer is the second most common cancer of the urinary tract, and overall it is among the top 10 cancers in men. Transitional cell carcinoma (TCC) is the most common type, with the majority being superficial disease, i.e. the tumour has not gone beyond the lamina propria. The main problem with superficial TCC is the high recurrence rate. Various forms of treatment methods have been attempted to reduce the recurrence rate, with intravesical bacillus Calmette-Guerin (BCG) being the most successful to date. In fact, intravesical BCG is one of the most successful forms of immunotherapy in the treatment of any form of cancer. This article is a general review of BCG in bladder cancer with an emphasis on the indication and mechanism of action in reducing recurrence and progression.
    Matched MeSH terms: BCG Vaccine/administration & dosage; BCG Vaccine/pharmacology; BCG Vaccine/therapeutic use*
  9. Loh KY
    Malays Fam Physician, 2011;6(2):85-86.
    PMID: 25606232 MyJurnal
    Mantoux test is a sensitive but non-specific in the diagnosis of active tuberculosis. The positive cut-off of 10 mm in a person without BCG and 15 mm with previous BCG is appropriate. The interpretation of Mantoux needs to be correlated to the patient’s clinical context. Mantoux test may have a role in assisting extrapulmonary tuberculosis and latent tuberculosis in children.
    Matched MeSH terms: BCG Vaccine
  10. Mohd Nor N, Musa M
    Tuberculosis (Edinb), 2004;84(1-2):102-9.
    PMID: 14670351 DOI: 10.1016/j.tube.2003.08.011
    The last few years have witnessed intense research on vaccine development against tuberculosis. This has been driven by the upsurge of tuberculosis cases globally, especially those caused by multi-drug-resistant Mycobacterium tuberculosis strains. Various vaccine strategies are currently being developed which can be broadly divided into the so-called living and non-living vaccines. Examples are attenuated members of the M. tuberculosis complex, recombinant mycobacteria, subunit proteins and DNA vaccines. Given current developments, we anticipate that recombinant BCG and DNA vaccines are the most promising. Multiple epitopes of M. tuberculosis may need to be cloned in a vaccine construct for the desired efficacy to be achieved. The technique of assembly polymerase chain reaction could facilitate such a cloning procedure.
    Matched MeSH terms: BCG Vaccine
  11. Jeffree MS, Ahmedy F, Ibrahim MY, Awang Lukman K, Ahmed K, Giloi N, et al.
    J Public Health Res, 2020 Jul 28;9(3):1757.
    PMID: 33117755 DOI: 10.4081/jphr.2020.1757
    Empowering marginalised urban islanders with limited health accessibility through knowledge transfer program for controlling pulmonary tuberculosis (PTB) requires a specific training module. The study was aimed to develop this training module by adapting and modifying the IMCI (Integrated Management of Childhood Illness) framework. Structuring the content for the knowledge and skills for PTB control in the module was based on the National Strategic Plan for Tuberculosis Control 2016-2020. A total of five knowledge and skills were structured: i) PTB disease and diagnosis, ii) PTB treatment, iii) preventive PTB measures, iv) prevention of malnutrition, and v) psychosocial discrimination. The IMCI framework was modified through 3 ways: i) identifying signs and symptoms of PTB, ii) emphasising the IMCI's 5 steps of integrated management: assess, diagnose, treat, counsel and detect, and iii) counseling on BCG immunisation, malnutrition, environmental modifications and stigma on PTB.
    Matched MeSH terms: BCG Vaccine
  12. Sodhy JS
    Bull Int Union Tuberc, 1974 Aug;49 suppl 1:28-9.
    PMID: 4468023
    Matched MeSH terms: BCG Vaccine
  13. Govindarajan KK, Chai FY
    Malays J Med Sci, 2011 Apr;18(2):66-9.
    PMID: 22135589
    Bacille Calmette-Guerin (BCG) vaccination for protection against tuberculosis has been in use for long. Although the vaccine is safe, its administration can result in complications such as BCG adenitis. We report here a series of children with BCG adenitis with a view to recognise and manage this condition. It is hoped that this case series would encourage the increased identification of this condition.
    Study site: Paediatric Surgical Unit, Department of Surgery, Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia
    Matched MeSH terms: BCG Vaccine
  14. Venugopalan B
    Med J Malaysia, 2004 Mar;59(1):20-5.
    PMID: 15535331 MyJurnal
    In the year 2001, 1459 Tuberculosis (TB) cases (43.1/100,000 population) were notified in Selangor. The highest age specific incidence rate was among those aged above 60 years and foreigners accounted for 15% of the cases notified. Fifteen percent of the TB cases were treated in the private sector where treatment efficacy and compliance could not be evaluated. Co- infection of Human Immunodeficiency Virus (HIV) infection with TB accounted for 51% of the TB deaths notified. Screening programmes in prisons and drug rehabilitation centres had detected 11.7% of HIV/TB coinfection among HIV positive inmates screened in these institutions.
    Matched MeSH terms: BCG Vaccine/administration & dosage
  15. Tye GJ, Lew MH, Choong YS, Lim TS, Sarmiento ME, Acosta A, et al.
    J Immunol Res, 2015;2015:916780.
    PMID: 26146643 DOI: 10.1155/2015/916780
    Development of vaccines for infectious diseases has come a long way with recent advancements in adjuvant developments and discovery of new antigens that are capable of eliciting strong immunological responses for sterile eradication of disease. Tuberculosis (TB) that kills nearly 2 million of the population every year is also one of the highlights of the recent developments. The availability or not of diagnostic methods for infection has implications for the control of the disease by the health systems but is not related to the immune surveillance, a phenomenon derived from the interaction between the bacteria and their host. Here, we will review the immunology of TB and current vaccine candidates for TB. Current strategies of developing new vaccines against TB will also be reviewed in order to further discuss new insights into immunotherapeutic approaches involving adjuvant and antigens combinations that might be of potential for the control of TB.
    Matched MeSH terms: BCG Vaccine/immunology
  16. Liam CK
    Med J Malaysia, 2001 Mar;56(1):107-11; quiz 112.
    PMID: 11503290
    Matched MeSH terms: BCG Vaccine/immunology
  17. Jeyakumar D
    Med J Malaysia, 1999 Dec;54(4):492-5.
    PMID: 11072468
    This retrospective study documents a strong correlation between tuberculin reactivity and the subsequent development of active tuberculosis in student nurses. 12% of the 25 student nurses with tuberculin reactions above 20 mm developed tuberculosis over a period of 2 years, compared to only 0.3% of the 341 student nurses with reactions of 20 mm or less. The implications of these findings for preventive therapy are discussed.
    Matched MeSH terms: BCG Vaccine/therapeutic use
  18. Hooi LN, Athiyah SO
    Med J Malaysia, 1994 Dec;49(4):327-35.
    PMID: 7674967
    A study was done on 638 infants with BCG related lymphadenitis seen between August 1990 and December 1993. Most infants (86.5%) had developed symptoms by six months after vaccination and the nodes became suppurative in 317. Surgical procedures were carried out in 82 cases and the rest were managed conservatively. The mean duration to resolution was 6.6 months (range 1 to 29 months). This outbreak was related to a change from the Japan to the Pasteur strain of BCG. The incidence remained high ( > 15 per 1000 live births) despite a dose reduction from 0.1 ml to 0.05 ml, but declined when the Japan strain was reintroduced in April 1992.
    Study site: Chest Clinic, Hospital Pulau Pinang, Malaysia
    Matched MeSH terms: BCG Vaccine/adverse effects*
  19. Chen ST, Choong MM
    Med J Malaya, 1971 Sep;26(1):15-9.
    PMID: 4258569
    Matched MeSH terms: BCG Vaccine*
  20. Sodhy JS
    Med J Malaysia, 1963 Sep;18:38-41.
    PMID: 14064295
    Matched MeSH terms: BCG Vaccine*
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links